Simplicity Wealth LLC Boosts Stock Holdings in Gilead Sciences, Inc. $GILD

Key Points

• Simplicity Wealth LLC increased its holdings in Gilead Sciences by 158.0% during the 2nd quarter, bringing its total shares to 11,108, valued at $1,232,000.
• Several analysts upgraded their ratings for Gilead Sciences, with Needham & Company and Daiwa America raising their targets to as high as $135.00, indicating strong positive sentiment among analysts.
• Gilead Sciences recently announced a quarterly dividend of $0.79 per share, equating to an annual yield of 2.8%, and had a payout ratio of 62.95%.

Simplicity Wealth LLC grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 158.0% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 11,108 shares of the biopharmaceutical company's stock after purchasing an additional 6,802 shares during the quarter. Simplicity Wealth LLC's holdings in Gilead Sciences were worth $1,232,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Southland Equity Partners LLC lifted its holdings in Gilead Sciences by 2.9% during the second quarter. Southland Equity Partners LLC now owns 3,285 shares of the biopharmaceutical company's stock worth $364,000 after buying an additional 92 shares during the period. Twelve Points Wealth Management LLC raised its position in shares of Gilead Sciences by 1.5% in the 2nd quarter. Twelve Points Wealth Management LLC now owns 6,499 shares of the biopharmaceutical company's stock worth $721,000 after acquiring an additional 98 shares in the last quarter. Argentarii LLC lifted its stake in shares of Gilead Sciences by 3.0% during the 1st quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company's stock worth $380,000 after purchasing an additional 99 shares during the last quarter. Investment Research & Advisory Group Inc. boosted its position in Gilead Sciences by 33.3% during the first quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 100 shares in the last quarter. Finally, Lodestar Private Asset Management LLC grew its stake in Gilead Sciences by 3.6% in the first quarter. Lodestar Private Asset Management LLC now owns 2,840 shares of the biopharmaceutical company's stock valued at $318,000 after purchasing an additional 100 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts have commented on GILD shares. Needham & Company LLC raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target for the company in a research report on Friday, July 25th. Daiwa America raised shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 19th. Royal Bank Of Canada raised their target price on shares of Gilead Sciences from $96.00 to $98.00 and gave the company a "sector perform" rating in a research note on Friday, August 8th. Weiss Ratings reaffirmed a "buy (b)" rating on shares of Gilead Sciences in a research report on Saturday, September 27th. Finally, JPMorgan Chase & Co. increased their price objective on Gilead Sciences from $135.00 to $145.00 and gave the company an "overweight" rating in a report on Tuesday, September 16th. Three analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $117.17.

Gilead Sciences Trading Up 0.8%

NASDAQ GILD opened at $113.58 on Tuesday. Gilead Sciences, Inc. has a 12-month low of $84.17 and a 12-month high of $121.83. The company has a fifty day simple moving average of $114.36 and a two-hundred day simple moving average of $110.01. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The stock has a market cap of $140.93 billion, a P/E ratio of 22.63, a P/E/G ratio of 0.77 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.96 by $0.05. The firm had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm's revenue was up 1.4% on a year-over-year basis. During the same period in the prior year, the firm earned $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were issued a dividend of $0.79 per share. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.8%. Gilead Sciences's payout ratio is 62.95%.

Insider Activity at Gilead Sciences

In other news, CEO Daniel Patrick O'day sold 10,000 shares of the company's stock in a transaction on Monday, September 29th. The shares were sold at an average price of $111.66, for a total value of $1,116,600.00. Following the sale, the chief executive officer directly owned 591,203 shares of the company's stock, valued at $66,013,726.98. This represents a 1.66% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Johanna Mercier sold 3,000 shares of the stock in a transaction on Monday, September 15th. The stock was sold at an average price of $113.57, for a total transaction of $340,710.00. Following the completion of the sale, the insider owned 113,193 shares in the company, valued at $12,855,329.01. The trade was a 2.58% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 82,000 shares of company stock worth $9,402,130 over the last quarter. Insiders own 0.27% of the company's stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.